Recent ORAL surveillance study demonstrated that RA patients aged ≥50 years with ≥1 additional cardiovascular risk factor (for example, current cigarette smoker, hypertension, diabetes mellitus) have higher risks of major adverse cardiovascular event (MACE) and cancers during a median follow-up of 4.0 years, comparing the combined tofacitinib doses (5 or 10 mg twice daily) with tumor necrosis factor inhibitors (TNFis) [33]. Here, TNF is linked to Hypertension.